FDA Clears IND for Ensoma's First-in-Class In Vivo Gene Therapy for X-Linked Chronic Granulomatous Disease
核心洞察
Ensoma (搜索)'s EN-374, designed to deliver a functional CYBB (搜索) gene directly to hematopoietic stem cells in vivo, has received FDA clearance to begin clinical trials for X-linked chronic granulomatous disease (搜索).
The therapy represents a potentially transformative approach for X-CGD (搜索) patients, offering a simpler, more accessible alternative to current treatments like stem cell transplantation or ex vivo gene therapies.
Following earlier rare pediatric disease and orphan drug designations, Ensoma (搜索) plans to initiate a Phase 1/2 clinical trial in Q4 2025, with initial enrollment of adult patients followed by pediatric cohorts.
Ensoma (搜索) has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for EN-374, a groundbreaking in vivo hematopoietic stem cell (HSC)-directed gene therapy for X-linked chronic granulomatous disease (搜索) (X-CGD (搜索)). This milestone follows the FDA's earlier granting of both rare pediatric disease and orphan drug designations for the therapy.
X-CGD (搜索) is a rare and severe genetic disorder affecting approximately 1 in 100,000-200,000 live births, with a median life expectancy of around 45 years. The condition, which accounts for 60-70% of all CGD (搜索) cases, is caused by mutations in the CYBB (搜索) gene that prevent neutrophils from effectively fighting infections, leaving patients vulnerable to recurrent and potentially life-threatening bacterial and fungal infections.
"The FDA's clearance of our EN-374 IND is a pivotal moment for Ensoma (搜索) that further establishes our unique in vivo HSC engineering platform and brings us one step closer to meaningfully improving outcomes for people living with X-CGD (搜索) and other chronic diseases," said Jim Burns, CEO of Ensoma.
Novel Therapeutic Approach
EN-374 represents the first in vivo HSC-directed therapy for X-CGD (搜索). The treatment employs virus-like particles (VLPs) to deliver payloads that efficiently engineer HSCs for sustained expression of a CYBB (搜索) transgene in neutrophils, thereby restoring function of the infection-fighting NADPH oxidase (搜索) enzyme complex critical for immune defense.
Unlike current treatment options—including antibiotics, antifungals, interferon gamma, and allogeneic stem cell transplantation—which offer limited benefits or come with significant burdens, EN-374 aims to provide a one-time treatment that addresses the underlying genetic cause of the disease.
Drew Dietz, M.D., MSCR, vice president of clinical development at Ensoma (搜索), highlighted the significant unmet need: "Current treatments offer limited benefit and/or come with significant burdens. EN-374 represents the first in vivo HSC-directed therapy for X-CGD (搜索), building on a mechanism that has been validated ex vivo."
The therapy is designed to function for any CYBB (搜索) mutation, potentially offering a simpler, safer, and more accessible approach compared to ex vivo gene therapies or stem cell transplantation.
Clinical Development Plans
Ensoma (搜索) has completed all manufacturing activities for EN-374, demonstrating reproducibility and scalability. The company anticipates initiating its Phase 1/2 clinical trial in Q4 2025.
The trial will evaluate the safety and potential efficacy of EN-374 and identify a dose for further clinical development in X-CGD (搜索). Adult participants with X-CGD will be enrolled in the dose-escalation part of the trial, followed by pediatric participants in a dose-expansion cohort.
"We have completed all manufacturing activities for EN-374, through which we have successfully demonstrated reproducibility and scalability, and anticipate initiating our Phase 1/2 clinical trial in Q4 2025," Burns added. "We are excited to explore the potential of EN-374 to offer a simpler, more accessible approach to restoring immune function in X-CGD (搜索) than HSC transplantation or ex vivo therapies."
Platform Potential Beyond X-CGD
Robert Peters, Ph.D., chief scientific officer of Ensoma (搜索), emphasized the broader implications of the company's technology: "One of the strengths of our platform is its modular nature – we can evaluate multiple products for a family of diseases in a single clinical trial by inserting different genes to address the various genetic forms of CGD (搜索), for example."
This approach could enable greater efficiency in clinical development and facilitate the regulatory process. The EN-374 program is expected to validate the potential of Ensoma (搜索)'s platform to develop future HSC-directed, one-time medicines for other genetic diseases, cancer, and immunologic conditions.
Regulatory Incentives
The rare pediatric disease designation, granted by the FDA for serious or life-threatening rare diseases primarily affecting children under 18 years, could make Ensoma (搜索) eligible to receive a Priority Review Voucher if a Biologics License Application for EN-374 is approved.
Additionally, the orphan drug designation provides potential benefits including up to seven years of market exclusivity after approval, tax credits for qualified clinical trials, and exemption from certain FDA fees.
Ensoma's Technology Platform
Ensoma (搜索)'s platform combines proprietary base editing and high-efficiency gene integration systems with high-capacity virus-like particles to provide one-time genetic medicines in an outpatient procedure.
The delivery system is based on VLPs that preferentially bind to hematopoietic stem cells, efficiently delivering DNA to the nucleus while de-targeting the liver. With a 35-kilobase cargo capacity, these VLPs can carry a diverse range of sophisticated genomic engineering tools capable of precise changes from single base edits to large multi-gene insertions, along with control elements for HSC-lineage cell specific expression.
Beyond CGD (搜索), Ensoma (搜索) is advancing preclinical programs in cancer and sickle cell disease (搜索), further demonstrating the versatility of its in vivo cellular engineering platform.